OBJECTIVE: To investigate the influence of age and gender on the prevalence and @entity65 ( @entity65 ) risk in Europeans presenting with the @entity209 ( @entity209 ). METHODS: Using 36 cohorts from the MORGAM-Project with baseline between 1982-1997, 69094 @entity1 and @entity1 aged 19-78 years, without known @entity65 , were included. During 12.2 years of follow-up, 3.7%/2.1% of @entity1 / @entity1 died due to @entity65 . The corresponding percentages for fatal and nonfatal @entity301 ( @entity301 ) and @entity64 were 8.3/3.8 and 3.1/2.5. RESULTS: The prevalence of @entity209 , according to modified definitions of the International @entity6 Federation (IDF) and the revised National @entity165 Education Program-Adult Treatment Panel III (NCEP-ATPIII), increased across age groups for both genders (P<0.0001); with a 5-fold increase in @entity1 from ages 19-39 years to 60-78 years (7.4%/7.6% to 35.4%/37.6% for IDF/NCEP-ATPIII) and a 2-fold increase in @entity1 (5.3%/10.5% to 11.5%/21.8%). Using multivariate-adjusted Cox regressions, the associations between @entity209 and all three @entity65 events were significant (P<0.0001). For IDF/NCEP-ATPIII in @entity1 and @entity1 , hazard ratio (HR) for @entity301 was 1.60/1.62 and 1.93/2.03, for @entity65 mortality 1.73/1.65 and 1.77/2.06, and for @entity64 1.51/1.53 and 1.58/1.77. Whereas in @entity1 the HRs for @entity65 events were independent of age ( @entity209 *age, P>0.05), in @entity1 the HRs for @entity301 declined with age (HRs 3.23/3.98 to 1.55/1.56; @entity209 *age, P=0.01/P=0.001 for IDF/NCEP-ATPIII) while the HRs for @entity64 tended to increase (HRs 1.31/1.25 to 1.55/1.83; @entity209 *age, P>0.05). CONCLUSION: In Europeans, both age and gender influenced the prevalence of @entity209 and its prognostic significance. The present results emphasise the importance of being critical of @entity209 in its current form as a marker of @entity65 especially in @entity1 , and advocate for a redefinition of @entity209 taking into account age especially in @entity1 .

Impact of age and gender on the prevalence and prognostic importance of the XXXX and its components in Europeans. The MORGAM Prospective Cohort Project.

@entity1 :: ('9606', 'Species') :: ['women', 'men'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity209 :: ('MESH:D008659', 'Disease') :: ['Metabolic Syndrome', 'MetS'] @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol']
@entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']
